Skip to content
Xalkori(crizotinib)
Xalkori (crizotinib) is a small molecule pharmaceutical. Crizotinib was first approved as Xalkori on 2011-08-26. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Xalkori
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Crizotinib
Tradename
Company
Number
Date
Products
XALKORICV SciencesN-202570 RX2011-08-26
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
xalkoriNew Drug Application2021-01-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
Agency Specific
FDA
EMA
Expiration
Code
CRIZOTINIB, XALKORI, PF PRISM CV
2029-07-14ODE-407
2028-01-14ODE-328
2025-07-14I-897
2024-01-14I-852
2023-03-11ODE-111
Patent Expiration
Patent
Expires
Flag
FDA Information
Crizotinib, Xalkori, Pf Prism Cv
82170572029-11-06DS, DP
78586432029-10-08DS, DP
78251372027-05-12U-3057, U-3058, U-3403
72300982025-08-26DP
87856322025-03-01DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01ED: Anaplastic lymphoma kinase (alk) inhibitors
— L01ED01: Crizotinib
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022891217112946
Large-cell lymphoma anaplasticD017728C84.634—3—9
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80962—419
Lung neoplasmsD008175C34.90251——7
Gene rearrangementD015321—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.0—4———4
Renal cell carcinomaD00229212——14
Colorectal neoplasmsD01517923———4
AdenocarcinomaD00023012———3
LymphomaD008223C85.9—3———3
Adenocarcinoma of lungD000077192—2——13
Liver neoplasmsD008113EFO_1001513C22.011———2
Squamous cell neoplasmsD01830711———2
Uveal neoplasmsD014604EFO_100123012———2
Breast neoplasmsD001943EFO_0003869C5011———2
Show 27 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—13————13
GlioblastomaD005909EFO_00005152————2
Castration-resistant prostatic neoplasmsD0641291————1
Large cell carcinomaD0182871————1
Diffuse intrinsic pontine gliomaD0000804431————1
Renal insufficiencyD051437HP_0000083N191————1
LeukemiaD007938C951————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinomaD002294————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCRIZOTINIB
INNcrizotinib
Description
Crizotinib is a 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) It has a role as an antineoplastic agent, a biomarker and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is an enantiomer of an ent-crizotinib.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
Identifiers
PDB5AAC
CAS-ID877399-52-5
RxCUI1148495
ChEMBL IDCHEMBL601719
ChEBI ID64310
PubChem CID11626560
DrugBankDB08865
UNII ID53AH36668S (ChemIDplus, GSRS)
Target
Agency Approved
ALK
ALK
Organism
Homo sapiens
Gene name
ALK
Gene synonyms
NCBI Gene ID
238
Protein name
ALK tyrosine kinase receptor
Protein synonyms
Anaplastic lymphoma kinase, anaplastic lymphoma receptor tyrosine kinase, CD246, CD246 antigen, mutant anaplastic lymphoma kinase
Uniprot ID
Q9Y4K6
Mouse ortholog
Alk (11682)
ALK tyrosine kinase receptor (P97793)
Alternate
MET
MET
Organism
Homo sapiens
Gene name
MET
Gene synonyms
NCBI Gene ID
4233
Protein name
hepatocyte growth factor receptor
Protein synonyms
HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met
Uniprot ID
Q9UPL8
Mouse ortholog
Met (17295)
hepatocyte growth factor receptor (P16056)
Variants
Clinical Variant
No data
Financial
Xalkori - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 12,592 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
627 adverse events reported
View more details